Q Apel Medical Raises $22 Million to Grow Highly Innovative Neurovascular Access Platform & Scott Huennekens Joins Board of Directors
Investment Will Be Used to Scale Product Platform, Expand Nationally, Internationally and Grow Team
News provided by
Share this article
Share this article
FREMONT, Calif., Feb. 11, 2021 /PRNewswire/ Q Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today it has raised $22 Million in Series C funding. The round included River Cities Capital, Soleus Capital, and incumbent investor Research Corporation Technologies (RCT). Scott Huennekens, former Chairman, CEO and President of Verb Surgical, and Carter McNabb, Managing Director, River Cities Capital, will join the Board of Directors.
Health tech giant Hillrom to acquire Seattle startup Bardy Diagnostics for $375M
January 19, 2021 at 10:31 am
Dr. Gust Bardy, founder of Bardy Diagnostics. (Bardy Photo)
Hillrom, a publicly-traded medical device and digital health company based in Chicago, will pay $375 million to acquire Seattle startup Bardy Diagnostics.
Founded in 2013, Bardy set out to change the way medical professionals monitor heart conditions with a non-invasive cardiac monitor patch that helps detect arrhythmia. The Carnation Ambulatory Monitor, or CAM for short, is designed to be worn comfortably for approximately a week, with the goal of improving patient compliance. It uses a unique circuit design and algorithms to process P-wave recording. Bardy claims that its device captures clearer and more accurate heart rhythms than competing electrocardiography (ECG) monitors.